Products
The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[5] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[6]
Antibe's lead drug, Otenaproxesul (formerly ATB-346, now known by its International Nonproprietary Name), is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). Otenaproxesul is being developed as a safer non-opiod analgesic for acute pain. Antibe is targeting the post-operative pain market and plans to broaden its application to include migraines, dysmenorrhea and dental pain. Unlike standard naproxen, Otenaproxesul does not induce damage to the gastrointestinal tract.[7] In May 2014, the company announced that it had completed pre-clinical studies on Otenaproxesul.[8] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[9] In mid-January 2015, the company announced that clinical trials for Otenaproxesul were being suspended due to safety concerns; clinical trials were restarted in March 2015.[10]
On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for Otenaproxesul.[11] On June 1, 2020, Antibe announced positive results for Otenaproxesul in its final Phase 2 trial – a dose ranging, efficacy study.[12] The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2023.[13]
On November 12, 2020, Antibe Therapeutics has moved to the TSX. In February 2021, Antibe announced a deal with Nuance Pharma, a Chinese pharmaceutical company, entitling them to $100 million in funding, with $20 million upfront.[14]
